Evidence map›Paper›PMID 11461980›Full record

ReviewJournal of the Royal Society of Medicine2001

Aldosterone as a determinant of cardiovascular and renal dysfunction.

M Epstein

Registry-linked trialAbstract readReview
In one paragraph

Review in Journal of the Royal Society of Medicine, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00291720 (Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?), which is not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00291720 phase2completednot on this mapstarted 2005, after this paper: background citation

Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?

TypeinterventionalSponsorUniversity Hospital BirminghamRan2005 to 2007Enrolled120ConditionsChronic Kidney Disease, Cardiovascular DiseaseArmsSpironolactone, Placebo
3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Reduced Weight Gain with Pioglitazone vs Vildagliptin inDiabetes, metabolic syndrome and obesity : targets and therapy · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Mineralocorticoid receptors in vascular function and disease.Molecular and cellular endocrinology · 2012
    Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Aldosterone stimulates surface expression of NHE3 in renal proximal brush borders.Pflugers Archiv : European journal of physiology · 2003
    Article
  16. Aldosterone: a risk factor for vascular disease.Current hypertension reports · 2003
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

M EpsteinDepartment of Medicine, University of Miami School of Medicine, Miami, FL 33125, USA. murraye@gate.net

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AldosteroneAngiotensin IIAnimalsCardiovascular DiseasesEndothelium, VascularFibrosisHumansKidney DiseasesMineralocorticoid Receptor AntagonistsNitric OxidePotassiumRandomized Controlled Trials as TopicSodiumSpironolactoneAldosteroneAngiotensin IIMineralocorticoid Receptor AntagonistsNitric OxidePotassiumSodiumSpironolactone

Identifiers

PMID11461980
PMCPMC1281630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.